Sorafenib

目录号:S7397 别名: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

规格 价格 库存 购买数量  
RMB 1205.41 现货
RMB 2214.52 现货
RMB 5503.41 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献62篇:

客户使用该产品的9个实验数据:

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。
靶点
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外研究

Sorafenib抑制野生型和V599E突变型B-Raf活性,IC50分别为22 nM 和 38 nM。Sorafenib也能有效抑制mVEGFR2 (Flk-1),mVEGFR3,mPDGFRβ,Flt3,和c-Kit,IC50分别为15 nM,20 nM,57 nM,58 nM,和68 nM。Sorafenib 能够较弱地抑制FGFR-1,IC50 为580 nM。Sorafenib对ERK-1,MEK-1,EGFR,HER-2,IGFR-1,c-Met,PKB,PKA,cdk1/cyclinB,PKCα,PKCγ,和pim-1没有活性。Sorafenib显著抑制NIH 3T3细胞中VEGFR2磷酸化,IC50 为 30 nM,也会抑制HEK-293细胞中Flt-3磷酸化,IC50 为20 nM。Sorafenib有效阻断大多数细胞中MEK 1/2 和 ERK 1/2磷酸化,但不阻断A549 或 H460细胞中该过程,同时不影响PKB通路的抑制。Sorafenib抑制HAoSMC 和 MDA-MB-231细胞的增殖,IC50分别为0.28 μM 和 2.6 μM。[1]除了抑制RAF/MEK/ERK信号通路,Sorafenib tosylate显著抑制eIF4E的磷酸化作用,并以MEK/ERK依赖的方式下调肝癌(HCC)细胞中Mcl-1水平。Sorafenib 抑制PLC/PRF/5 和HepG2细胞的增殖,IC50分别为6.3 μM 和 4.5 μM,并诱导显著的细胞凋亡。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M3y4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMECwNFA{ODNizszN M1zOeXNCVkeHUh?=
MONO-MAC-6 M4G4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HDTGlEPTB;MD6wNFQyQCEQvF2= NYLkcllVW0GQR1XS
ALL-PO MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTETWM2OD1yLkCzNVg1KM7:TR?= MYHTRW5ITVJ?
NKM-1 NHXBcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWxR41KSzVyPUCuNFc1OTZizszN MWjTRW5ITVJ?
CGTH-W-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMkWwNlIh|ryP NF6xZ4FUSU6JRWK=
BB65-RCC NXTMOW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Xj[GlEPTB;MD60O|A4OyEQvF2= MYHTRW5ITVJ?
NOS-1 NYj5OWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rsWGlEPTB;MD61OlM3KM7:TR?= NVrz[oNPW0GQR1XS
SH-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHJTWM2OD1yLk[1OlE{KM7:TR?= NYPpV2ZjW0GQR1XS
HOP-62 NWXRfog6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2naOWlEPTB;MD64OVA5QCEQvF2= MkfnV2FPT0WU
HCC2998 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwOEi4NVgh|ryP NWOxWpdxW0GQR1XS
GDM-1 NYL4cY06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwOUC2PVgh|ryP MkPaV2FPT0WU
KM12 M172VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfzS2VOUUN3ME2xMlAzODl6IN88US=> MUPTRW5ITVJ?
LB2518-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DwcGlEPTB;MT6yNFgxQSEQvF2= MXXTRW5ITVJ?
NCI-H1436 NHS0d|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmwTWM2OD1zLkKxOlc5KM7:TR?= NH7WO2xUSU6JRWK=
EM-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrRTWM2OD1zLkO1OVc5KM7:TR?= M4\NfHNCVkeHUh?=
LAMA-84 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjXTWM2OD1zLkO3OlQ5KM7:TR?= Mn7WV2FPT0WU
KG-1 M2DSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT3XotVUUN3ME2xMlQ4QTN3IN88US=> NGe5NmdUSU6JRWK=
A388 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwNUmxOlUh|ryP MULTRW5ITVJ?
no-10 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO1cpJDUUN3ME2xMlYyPzJ4IN88US=> M{Oz[HNCVkeHUh?=
SF126 NWfheJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH4TWM2OD1zLk[zPFEzKM7:TR?= MnflV2FPT0WU
MEG-01 NHz6cHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe3WXpKSzVyPUGuPFA6QCEQvF2= NILp[FJUSU6JRWK=
A3-KAW NUDkTFE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe4PXZKSzVyPUGuPFg1OiEQvF2= M2\od3NCVkeHUh?=
D-247MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrkTWM2OD1{LkG0OFgh|ryP MofLV2FPT0WU
OVCAR-4 NHPhOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXhU4VSUUN3ME2yMlIyOzl|IN88US=> NVPIUll3W0GQR1XS
NCI-SNU-1 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;iXZhKSzVyPUKuN|E3OiEQvF2= NFi4Sm1USU6JRWK=
NCI-H2171 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfwd2dKSzVyPUKuN|k4PjRizszN Ml30V2FPT0WU
SIG-M5 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nqfWlEPTB;Mj60NlI1OiEQvF2= M1ew[HNCVkeHUh?=
BE-13 NXHJPG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJwNkm2NFkh|ryP NWKxXnN{W0GQR1XS
K052 NYfkclRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfl[GRKSzVyPUKuO|Q3OTZizszN NUnIbYxvW0GQR1XS
L-540 M13lSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jHfGlEPTB;Mj63OVc5QSEQvF2= MX3TRW5ITVJ?
KMOE-2 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni5TWM2OD1{LkixN|Uh|ryP MVjTRW5ITVJ?
MFH-ino MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJwOUKxPFUh|ryP NYnNdYVPW0GQR1XS
HL-60 NH70T|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jLN2lEPTB;Mz6wOlI6QSEQvF2= M{DFNHNCVkeHUh?=
HCC2218 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPkfIc3UUN3ME2zMlEzODB|IN88US=> M4TBTHNCVkeHUh?=
TE-5 NWXiXng5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDtTY1KSzVyPUOuNVMyPjJizszN MWnTRW5ITVJ?
MZ1-PC NVTzNFBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnvdmJCUUN3ME2zMlQ4PTB7IN88US=> NVG2bYpTW0GQR1XS
MRK-nu-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrjWoxKSzVyPUOuOlE1PjhizszN NFjPSIpUSU6JRWK=
MZ7-mel NF;qVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnJdIE3UUN3ME2zMlY3ODl7IN88US=> MonSV2FPT0WU
BC-1 NIfU[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i5d2lEPTB;Mz63OFAzKM7:TR?= NIrjZ4lUSU6JRWK=
ST486 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP0dFNKSzVyPUOuPFM3PzNizszN NVXaZoJ[W0GQR1XS
KS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:yVmNKSzVyPUOuPFgyQThizszN NXnURWZrW0GQR1XS
SK-NEP-1 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISzRmJKSzVyPUSuNVY5OTVizszN MULTRW5ITVJ?
BC-3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzScW1RUUN3ME20MlI{OzlzIN88US=> MWPTRW5ITVJ?
NCI-H1581 M4rDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;hfWlEPTB;ND6yPFc6QCEQvF2= NHHacohUSU6JRWK=
MHH-PREB-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX6OpJYUUN3ME20MlQxPDh2IN88US=> MoPHV2FPT0WU
NOMO-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTRwNEi5NFUh|ryP MnO1V2FPT0WU
QIMR-WIL NEfwUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf5UW5KSzVyPUWuNFczQTRizszN M3HJV3NCVkeHUh?=
SF539 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm3TWM2OD13LkGzNlI4KM7:TR?= NHPJbWNUSU6JRWK=
TE-12 NFv1dXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HaVGlEPTB;NT6yOFkzQSEQvF2= M2P5XHNCVkeHUh?=
NCI-H510A M3PSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnGTWM2OD13LkSxOlg2KM7:TR?= MVzTRW5ITVJ?
JAR Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPkT2VRUUN3ME21MlUxQDJ2IN88US=> NEjUZllUSU6JRWK=
no-11 M1TYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H0dGlEPTB;NT63N|U3QCEQvF2= NETwUopUSU6JRWK=
BV-173 NIXNcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLjTWM2OD13Lkm1OlgzKM7:TR?= M3PQNHNCVkeHUh?=
SR MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe4TWdnUUN3ME22MlAxPjd6IN88US=> MXHTRW5ITVJ?
MOLT-16 Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLyTWM2OD14LkK1NlY3KM7:TR?= M3;5cnNCVkeHUh?=
MZ2-MEL MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTZwM{G4N|kh|ryP M4P6WHNCVkeHUh?=
SW954 NGDhWWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fuV2lEPTB;Nj60OVg3PiEQvF2= NEPNXVdUSU6JRWK=
ML-2 M2S4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTZwNUK4OFkh|ryP M4DMc3NCVkeHUh?=
OCI-AML2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnSzTWM2OD14Lk[xNFYzKM7:TR?= NV:yepRxW0GQR1XS
SIMA NF74R3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTdwMECxNFEh|ryP MVLTRW5ITVJ?
DOHH-2 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXmyWItFUUN3ME23MlA2Pjd4IN88US=> M3jIeXNCVkeHUh?=
697 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPPTWM2OD15LkC1PVg6KM7:TR?= M{fQZnNCVkeHUh?=
NB1 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPsVXFKSzVyPUeuOFA1ODdizszN NHPpWWdUSU6JRWK=
D-392MG NIrKTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVS4b|QxUUN3ME23MlYzPjZ|IN88US=> NF\yNnVUSU6JRWK=
ES8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD2TWM2OD15Lke2OVA{KM7:TR?= NI\mcXNUSU6JRWK=
RPMI-8226 M3\KeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdwOES1NVEh|ryP NGjoVnBUSU6JRWK=
IST-MEL1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\xXVdKSzVyPUiuOFAxODJizszN M3nucXNCVkeHUh?=
NB14 NHjIbnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\OTWM2OD16Lk[zNVM{KM7:TR?= M{nVcXNCVkeHUh?=
HD-MY-Z Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjTUY1KSzVyPUiuOlM4PDZizszN Mme0V2FPT0WU
TE-10 M2HVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRThwN{[zOVMh|ryP Ml7aV2FPT0WU
LC-1F NE[wS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL4N5lKSzVyPUmuNVA5OzRizszN M4XZRXNCVkeHUh?=
OS-RC-2 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{CyXmlEPTB;OT6xNVI1OyEQvF2= M2P6PXNCVkeHUh?=
NCI-SNU-16 NX7EfHY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK5fXRKSzVyPUmuNlExOjZizszN M{ez[nNCVkeHUh?=
SHP-77 M3PiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfSVphKSzVyPUmuO|E3PjJizszN NXG1WpY{W0GQR1XS
A4-Fuk NFS0cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzOTWM2OD17Lke1OlEh|ryP M2njUnNCVkeHUh?=
NB6 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XLN2lEPTB;OT63OlAzQSEQvF2= MkXXV2FPT0WU
JiyoyeP-2003 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzWTWM2OD1zMD60O|Q2KM7:TR?= MXXTRW5ITVJ?
DMS-114 NX\iWmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[1TWM2OD1zMD61OFQyKM7:TR?= NYi1[o9mW0GQR1XS
NB7 NY\sbGdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULRdXpQUUN3ME2xNE44PTJ4IN88US=> MUTTRW5ITVJ?
NCI-H747 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPqOGdKSzVyPUGxMlEzOTZizszN NVnoXFVyW0GQR1XS
HH NWTHSY93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH74c5FKSzVyPUGxMlM5PzZizszN NHzkT2RUSU6JRWK=
EW-18 NYfLdVhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvLUopKSzVyPUGxMlkxPDRizszN MX7TRW5ITVJ?
CHP-126 M4TNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnITWM2OD1zMT65O|M5KM7:TR?= MkTQV2FPT0WU
NTERA-S-cl-D1 NVW4PI5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPDXJZtUUN3ME2xNk4xOjd6IN88US=> MYXTRW5ITVJ?
DEL MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7rRYFKSzVyPUGyMlA6QDVizszN NV:2TIVRW0GQR1XS
LU-139 NIq3c5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPkT4R[UUN3ME2xNk42PDF|IN88US=> NULiXms4W0GQR1XS
P30-OHK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFribmlKSzVyPUGyMlU1PzlizszN NWf3bFNtW0GQR1XS
NCI-H1522 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIX4blhKSzVyPUGyMlc1PiEQvF2= MYDTRW5ITVJ?
NCI-H1299 MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzDTWM2OD1zMz6yPVEyKM7:TR?= M{XXOXNCVkeHUh?=
UACC-257 MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfyTWM2OD1zMz61NVI3KM7:TR?= MXTTRW5ITVJ?
Calu-6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF|Lk[wOFYh|ryP NXjDZnZiW0GQR1XS
NCI-H1882 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDxNpNKSzVyPUGzMlg2PTVizszN NI\xXYxUSU6JRWK=
BB30-HNC NEnJU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy4UYZVUUN3ME2xOE4xPjB7IN88US=> MlTlV2FPT0WU
ES1 NVjFUGFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGzfW9KSzVyPUG0MlE2PTFizszN MkTGV2FPT0WU
NCI-H1694 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfIcmhKSzVyPUG0MlQ5OTFizszN NIrwVZNUSU6JRWK=
IST-SL1 NFnGOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLaTWM2OD1zND65OlE3KM7:TR?= MmizV2FPT0WU
ECC4 NITqRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPQTWM2OD1zNT6wOVU5KM7:TR?= NFTH[W9USU6JRWK=
MDA-MB-134-VI MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW2dIljUUN3ME2xOU41OTNzIN88US=> NEDWbndUSU6JRWK=
SCH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF3LkS3Nlgh|ryP NI\De3lUSU6JRWK=
SK-N-FI NW\hNItmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LsU2lEPTB;MUWuOlU{PCEQvF2= MkjHV2FPT0WU
HDLM-2 M{jzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrRTWM2OD1zNj6wO|E1KM7:TR?= MV;TRW5ITVJ?
Ramos-2G6-4C10 NF;hNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF4LkGyPVch|ryP MknXV2FPT0WU
EW-24 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ft[GlEPTB;MU[uNVY3OSEQvF2= MoP5V2FPT0WU
NCI-H2141 NU[wS2ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDCTWM2OD1zNj6xPFkh|ryP NFPl[3FUSU6JRWK=
LC4-1 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\M[FdQUUN3ME2xOk43OTF7IN88US=> MkH5V2FPT0WU
HT-144 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Ph[2lEPTB;MUeuNFA3KM7:TR?= NUHaR45OW0GQR1XS
SK-MEL-1 NGHPWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTBO3NNUUN3ME2xO{4xODd{IN88US=> MY\TRW5ITVJ?
SCC-15 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr2SZJKSzVyPUG3MlE3OzhizszN M2LrbXNCVkeHUh?=
C8166 Mn3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF5Lk[4N|Mh|ryP MYrTRW5ITVJ?
GOTO M3;2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3WWFNKSzVyPUG3Mlg{PDRizszN NYP0T|FKW0GQR1XS
COR-L279 NVfhPYJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DpVmlEPTB;MUiuNVM3OiEQvF2= MWXTRW5ITVJ?
K-562 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzpWmxYUUN3ME2xPE44OTR|IN88US=> MUDTRW5ITVJ?
ES3 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnsXnZ1UUN3ME2xPE45ODRzIN88US=> MYjTRW5ITVJ?
LU-165 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;Ce2J1UUN3ME2xPU44ODB6IN88US=> Ml6zV2FPT0WU
KM-H2 M2LaNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\xTWM2OD1{MD6zNVg1KM7:TR?= NHfrfppUSU6JRWK=
RL NEPlTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTmZoNKSzVyPUKwMlk3QTJizszN NEHXXIZUSU6JRWK=
EW-3 NGS0S4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT0PFNKSzVyPUKxMlE5QDlizszN MWjTRW5ITVJ?
A101D Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\CTWM2OD1{MT6zO|UzKM7:TR?= MX7TRW5ITVJ?
HUTU-80 M{PNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHPW5Z{UUN3ME2yNU4{QTR4IN88US=> MU\TRW5ITVJ?
NCI-H23 NF;DXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlziTWM2OD1{MT6zPVkzKM7:TR?= NIjyemRUSU6JRWK=
PF-382 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHkTWM2OD1{MT60OFA{KM7:TR?= M3nZbXNCVkeHUh?=
LB373-MEL-D M1ztb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlP6TWM2OD1{MT61OlE2KM7:TR?= M4LWdnNCVkeHUh?=
TE-8 MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzo[lFmUUN3ME2yNU43Ozl2IN88US=> MV7TRW5ITVJ?
TE-9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PIV2lEPTB;MkGuPFUyOyEQvF2= NYfaUVN4W0GQR1XS
Daudi MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJzLkmzNFQh|ryP M4DLRnNCVkeHUh?=
D-542MG NEjBPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjmZoFKSzVyPUKyMlAzPTZizszN MoHmV2FPT0WU
U-698-M MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHLeo1KSzVyPUKyMlQ3ODNizszN MlPwV2FPT0WU
ES6 M1W4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD6TWM2OD1{Mj63N|Y3KM7:TR?= MojhV2FPT0WU
DU-4475 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfQTWM2OD1{Mz64PFk4KM7:TR?= M{niSHNCVkeHUh?=
ECC12 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjsSnVHUUN3ME2yOE4zQDB|IN88US=> NGewNFVUSU6JRWK=
C2BBe1 NEn3SmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHZbVBKSzVyPUK0MlMzOzlizszN MWjTRW5ITVJ?
IST-SL2 NXvRfGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTxRnRXUUN3ME2yOE41OzZ{IN88US=> MnPoV2FPT0WU
DJM-1 NXHXW3RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ2LkWyNlEh|ryP NEDR[YRUSU6JRWK=
DMS-153 M2f0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nFRWlEPTB;MkSuPFYyPCEQvF2= MWDTRW5ITVJ?
NB13 M2XOXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkW2TWM2OD1{NT6wNlY2KM7:TR?= MV7TRW5ITVJ?
SK-N-DZ M2P6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDYWJJOUUN3ME2yOk4{PDF2IN88US=> MnnEV2FPT0WU
COR-L88 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jjPGlEPTB;Mk[uOVc6PiEQvF2= NWnh[|NCW0GQR1XS
LU-65 NUXyVJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojZTWM2OD1{Nj64OVM2KM7:TR?= Mk\vV2FPT0WU
TGBC1TKB NHrmXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrTTlVKSzVyPUK2Mlk5OjhizszN NYjCO4JoW0GQR1XS
THP-1 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vyemlEPTB;MkeuNlE1OSEQvF2= NU\QWHZlW0GQR1XS
ONS-76 NFTDUItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDTWM2OD1{Nz6zN|Ih|ryP MV;TRW5ITVJ?
LC-2-ad MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvKXYl1UUN3ME2yO{43OjNzIN88US=> M4rId3NCVkeHUh?=
EW-13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG1[5NjUUN3ME2yPU4yPzR4IN88US=> Ml7VV2FPT0WU
MS-1 NUPo[XZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyxcFVKSzVyPUOwMlczPzhizszN MmXnV2FPT0WU
NCI-H2227 NHTO[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[yOlF4UUN3ME2zNE46QDB4IN88US=> MlLsV2FPT0WU
LXF-289 M4TjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTNzLkS0PVIh|ryP NYjsUFBpW0GQR1XS
MC116 M4PwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN{LkC4NlYh|ryP MXnTRW5ITVJ?
EVSA-T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN{LkK1PFUh|ryP MWHTRW5ITVJ?
CTB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfKTXZKSzVyPUOzMlEyODFizszN MYjTRW5ITVJ?
COLO-320-HSR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3FOXdKSzVyPUOzMlE3ODNizszN NHuy[JFUSU6JRWK=
NCI-H2196 NUGxXlFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrrV2I5UUN3ME2zN{4zPTV5IN88US=> M1Ozb3NCVkeHUh?=
LB2241-RCC NGfDUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PKNWlEPTB;M{OuN|E{PSEQvF2= NYH0[pFtW0GQR1XS
LS-513 M4niO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO3TWM2OD1|Mz64OlM5KM7:TR?= M2PR[nNCVkeHUh?=
LP-1 M1PWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DBemlEPTB;M{OuPVk2PiEQvF2= M13hfHNCVkeHUh?=
A253 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTN2LkKyPVYh|ryP NH32cYdUSU6JRWK=
SK-MM-2 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLuVXdKSzVyPUO0Mlk1PTFizszN MmfIV2FPT0WU
NCI-H1963 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLK[FNLUUN3ME2zOU4{ODd{IN88US=> MYnTRW5ITVJ?
MMAC-SF NXzOe21tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O2XWlEPTB;M{WuPFc5PSEQvF2= M1eyNHNCVkeHUh?=
LB831-BLC M3L5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN4LkC2OVQh|ryP NV25enRPW0GQR1XS
WSU-NHL Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:3TmZCUUN3ME2zOk4yPjRizszN NFjVNZVUSU6JRWK=
CESS NYmyZXV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TwXmlEPTB;M{[uNlg1QCEQvF2= MYXTRW5ITVJ?
NEC8 NGTU[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHkRnhKSzVyPUO2MlU5OzVizszN Ml\RV2FPT0WU
KNS-42 NXLmXGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTN5LkGyN|ch|ryP NH2wcWVUSU6JRWK=
MHH-CALL-2 NYL3VYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:5WYdKSzVyPUO3MlE5OjFizszN MoTVV2FPT0WU
K5 M3TDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP3dm9KSzVyPUO4MlQ{KM7:TR?= MlTiV2FPT0WU
CP66-MEL Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEm1ZWZKSzVyPUO5MlA4OzNizszN MnrIV2FPT0WU
OPM-2 NXu2cIk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN7Lki0N|Ih|ryP MoP4V2FPT0WU
IST-MES1 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD12MD6zNFk3KM7:TR?= NU\LNpJKW0GQR1XS
EC-GI-10 NXX0doExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRzLkW4NFUh|ryP Mn32V2FPT0WU
CTV-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTR{Lki0NFYh|ryP M{\qXHNCVkeHUh?=
DG-75 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKxTWM2OD12Mz63OVk2KM7:TR?= NGXBR21USU6JRWK=
KNS-81-FD NHjLVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvZZY9KSzVyPUS1MlQxPThizszN Mkf5V2FPT0WU
NCI-H82 MnLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLaUm0{UUN3ME20OU42PzV6IN88US=> NEnPZoRUSU6JRWK=
RPMI-8866 NWP1TZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PFUmlEPTB;NE[uNVg4OyEQvF2= MXzTRW5ITVJ?
ACN NVjMclh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDtW4d6UUN3ME20Ok41OzRizszN NXjMZWxIW0GQR1XS
NCI-H1395 NXnBNGFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR4LkS3OVYh|ryP MXvTRW5ITVJ?
NCI-H209 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rhfGlEPTB;NEeuNVQxPSEQvF2= MYHTRW5ITVJ?
TGW MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTYTWM2OD12OT6wO|kyKM7:TR?= Mn7XV2FPT0WU
NCI-H748 NEnufpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17KXGlEPTB;NEmuOFc2OyEQvF2= Mnv5V2FPT0WU
EKVX NH7hNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTR7Lk[2Nlgh|ryP M4f1UnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

体内研究 Sorafenib(~60 mg/kg)口服给药,对各种人肿瘤异种移植模型,包括MDA-MB-231,Colo-205,HT-29,DLD-1,NCI-H460,和A549表现出广谱的、剂量依赖性抗肿瘤活性,而没有毒性。与抗肿瘤功效相联系,Sorafenib 治疗有效抑制HT-29 和 MDA-MB-231异种移植物中MEK 1/2磷酸化和pERK 1/2水平,但对Colo-205异种移植物没有作用,并且也能显著抑制MDA MB-231,HT-29 和 Colo-205肿瘤异种移植物中肿瘤微血管面积(MVA)和微血管密度(MVD)。[1] 在SCID小鼠体内,Sorafenib治疗对PLC/PRF/5肿瘤异种移植产生剂量依赖性生长抑制,10 mg/kg和30 mg/kg剂量下,TGIs分别为49%和78%,与ERK 和 eIF4E磷酸化抑制,微血管面积减少,和肿瘤细胞凋亡的诱导相一致。[2] Sorafenib通过下调NF-κB介导的Mcl-1 和 cIAP2表达的作用机制使bax-/-细胞对TRAIL剂量依赖性敏感。 Sorafenib (30-60 mg/kg) 与 TRAIL (5 mg/kg)结合对TRAIL抗性HCT116 bax-/-和HT29肿瘤异种移植物表现出显著的功效。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

生化检测:

重组杆状病毒表达的Raf-1 (残基305–648)和 B-Raf (残基 409–765)以融合蛋白纯化。全长人MEK-1由PCR产生,并以大肠杆菌裂解物中的融合蛋白纯化。将Sorafenib加入到含Raf-1 (80纳克),或B-Raf (80 纳克) 以及MEK-1 (1 微克) 混合物的实验缓冲液[20 mM Tris (pH 8.2),100 mM NaCl,5 mM MgCl2,和0.15% β-巯基乙醇]中,DMSO终浓度为1%。加入25微升10 μM γ[33P]ATP (400 Ci/mol)启动Raf激酶试验(终体积50微升),并在32 °C下培育25分钟。磷酸化的MEK-1通过过滤到磷酸纤维素板上采集,使用1%磷酸洗掉未结合的放射性。微波炉加热干燥后,使用β型板计数器量化过滤器结合放射性。人VEGFR2 (KDR)激酶域被表达,并从Sf9裂解物中纯化。VEGFR2的时间分辨荧光分析法能量转移测试在96孔不透明板中以时间分辨荧光分析法能量转移格式进行。最终反应条件如下:1 到10 μM ATP,25 nM poly GT生物素,2 nM 铕标记的磷酸(p)-酪氨酸抗体(PY20),10 nM APC,1% DMSO 终浓度的1 到 7 nM 细胞质激酶域,50 mM HEPES (pH 7.5),10 mM MgCl2,0.1 mM EDTA,0.015% Brij-35,0.1 毫克/毫升BSA,和0.1% β-巯基乙醇。反应体积为100微升,加入酶启动反应。反应启动~1.5 到 2.0小时后,板以615 和 665 nM在Perkin-Elmer VictorV多标记分析仪上读数。信号按如下比率计算:对每孔(665 nm/615 nM) × 10,000。对IC50的产生,在酶起始反应之前加入Sorafenib。50倍的库存板由Sorafenib在50% DMSO/50%蒸馏水溶液中连续稀释制得。最终Sorafenib在1% DMSO中的浓度范围为10 μM 到 4.56 nM。
细胞实验:[1]
+ 展开
  • Cell lines: MDA-MB-231,和 HAoSMC
  • Concentrations: 溶解于DMSO,终浓度为~10 μM
  • Incubation Time: 72小时
  • Method: 细胞在逐渐增加浓度的Sorafenib下暴露72小时。细胞数通过Cell TiterGlo ATP发光测定试剂盒进行定量。该试验通过测定基于细胞中ATP量的发光信号,测量每孔中的活细胞。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 雌性 NCr-nu/nu 小鼠,皮下植入MDA-MB-231,Colo-205,HT-29,H460,或 A549 细胞
  • Formulation: 以4倍(4 ×储备溶液,稀释为1 ×)溶解于聚氧乙烯蓖麻油/乙醇(50:50)
  • Dosages: ~60 mg/kg
  • Administration: 口服,每天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次加入纯溶剂:
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.82
化学式

C21H16ClF3N4O3

CAS号 284461-73-0
稳定性 powder
别名 BAY 43-9006

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Related Antibodies

Raf Signaling Pathway Map

相关Raf产品

Tags: 购买Sorafenib | Sorafenib供应商 | 采购Sorafenib | Sorafenib价格 | Sorafenib生产 | 订购Sorafenib | Sorafenib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID